European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

MT Newswires Live09-04

European equities traded in the US as American depositary receipts were flat late Wednesday morning, nudging 0.04% lower to 1,445.63 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies Genfit (GNFT) and Cellectis (CLLS), which rose 3.8% and 2.6% respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and telecommunications company VEON (VEON), which were up 1.8% and 1.6% respectively.

The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and biopharmaceutical company Calliditas Therapeutics (CALT), which fell 12% and 2.6% respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which lost 1.5%.

From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and software firm Endava (DAVA), which increased 3.6% and 3.4% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and telecommunications operator Vodafone Group (VOD), which advanced 3.2% and 1.5% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which lost 8.1% and 4.4% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Amarin (AMRN), which were down 2.5% and 1.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment